Department of Urology and Population Health, New York University and Manhattan Veterans Affairs Medical Center, New York, New York.
Division of Experimental Oncology, Unit of Urology URI, IRCCS Ospedale San Raffaele, University Vita-Salute San Raffaele, Milan, Italy.
J Urol. 2020 Jan;203(1):145-150. doi: 10.1097/JU.0000000000000451. Epub 2019 Jul 17.
North American studies have revealed that about 3% to 7% of opioid naïve surgical patients transition to chronic opioid use after a single prescription. We examined the risk of chronic opioid use following radical prostatectomy using nationwide Swedish data.
A total of 25,703 men in the National Prostate Cancer Register of Sweden who underwent radical prostatectomy were linked to the Prescribed Drug Register. Opioid use was assessed at 3 times, including baseline (13 months to 1 month preoperatively), perioperatively (1 month before and after) and postoperatively (1 to 12 months). Multivariable logistic regression was done to identify predictors of new late use (1 or more opioid prescriptions in 3 consecutive months more than 2 months after surgery).
Overall 16,368 men (64%) filled an opioid prescription during the 13 months before or after surgery. The use of strong opioids increased with time and the use of weak opioids decreased. Of the men 1.9% had opioid prescriptions during the baseline period, followed by a spike to 59% around the time surgery, which sharply decreased in month 2 postoperatively. However, thereafter the proportion of men with opioid prescriptions remained slightly higher at 2.2% compared to the baseline before radical prostatectomy. Of chronic late users 57% were previous users and 43% were new chronic users. Higher cancer risk category, greater comorbidity, unmarried status and low educational level were associated with the risk of new chronic opioid use.
Slightly more than half of male Swedish patients filled an opioid prescription after radical prostatectomy and less than 1% became chronic opioid users. These rates are lower than in previous studies of postoperative opioid use from North America.
北美研究显示,约 3%至 7%的初次接受阿片类药物治疗的手术患者在单次处方后转为慢性阿片类药物使用者。我们使用全国性的瑞典数据研究了根治性前列腺切除术后慢性阿片类药物使用的风险。
在瑞典国家前列腺癌登记处接受根治性前列腺切除术的 25703 名男性患者与处方药物登记处进行了关联。在 3 个时间点评估了阿片类药物的使用情况,包括基线(术前 13 个月至 1 个月)、围手术期(术前 1 个月和术后)和术后(术后 1 至 12 个月)。采用多变量逻辑回归确定新的晚期使用(术后 2 个月以上连续 3 个月内使用 1 种或多种阿片类药物处方)的预测因素。
总体而言,16368 名男性(64%)在手术前后 13 个月内开具了阿片类药物处方。强阿片类药物的使用随着时间的推移而增加,弱阿片类药物的使用则减少。在基线期间,有 1.9%的男性开具了阿片类药物处方,随后在手术时增加到 59%,术后第 2 个月急剧下降。然而,此后,与根治性前列腺切除术之前的基线相比,开具阿片类药物处方的男性比例仍略高,为 2.2%。慢性晚期使用者中,57%为既往使用者,43%为新的慢性使用者。更高的癌症风险类别、更高的合并症、未婚状态和低教育水平与新的慢性阿片类药物使用风险相关。
略多于一半的瑞典男性患者在根治性前列腺切除术后开具了阿片类药物处方,不到 1%的患者成为慢性阿片类药物使用者。这些比率低于北美之前研究的术后阿片类药物使用情况。